

Scaling Low-cost Biomedical Devices: Challenges and Successes in Global Health Deployment

Daniel Torres*

Department of Biomedical Engineering, University of Tunis El Manar, Tunis, Tunisia

Introduction

Low-cost biomedical devices are often celebrated as game-changers in the quest to expand healthcare access in Low- and Middle-Income Countries (LMICs). By providing affordable, reliable and context-appropriate alternatives to expensive equipment, such devices have the potential to address diagnostic and treatment gaps that hinder effective care in underserved communities. However, the journey from prototype to widespread implementation is fraught with challenges that are often underestimated. While innovative low-cost solutions routinely emerge from universities, start-ups and research labs, relatively few make it to sustained field deployment at scale. The so-called “valley of death” between innovation and adoption is particularly wide in global health, where issues of regulation, supply chain, policy alignment and local trust can impede even the most promising devices. This commentary explores the real-world complexities of scaling low-cost biomedical technologies, focusing on the balance between affordability, performance, sustainability and acceptance. Drawing from global health experiences, it also highlights successful case studies that have managed to overcome these barriers, offering a roadmap for innovators and stakeholders alike. The goal is not merely to innovate, but to implement to ensure that cost-effective devices do not sit idle in laboratories or warehouses but serve the people who need them most [1-2].

Description

The development of low-cost biomedical devices typically begins with a compelling idea to address a high-burden health issue using frugal engineering and locally available materials. Devices like handheld ECGs, paper-based diagnostic strips, neonatal warmers and manual ventilators have all shown promise in laboratory and pilot settings. Yet when these devices are introduced to broader healthcare systems, a new set of challenges arises. Regulatory approval, even for simple technologies, can be time-consuming and costly—often beyond the reach of small developers. Furthermore, devices must prove their reliability not just under controlled conditions but in variable field environments, where humidity, power outages, dust and supply chain disruptions are common. User training and acceptance also pose significant hurdles, as healthcare workers may be hesitant to adopt unfamiliar equipment, particularly if it deviates from internationally recognized standards. Maintenance and spare parts availability become critical in resource-limited areas, where technical support is scarce. Additionally, procurement systems often favor established vendors, making it difficult for new technologies to gain institutional footholds. This is compounded by a lack of market intelligence and weak commercialization pathways in many LMICs. In many cases, innovators are not

prepared for the realities of business development, distribution logistics and customer service in fragmented health systems. Thus, even the most affordable and technically sound devices can struggle to achieve long-term uptake if they are not embedded within a supportive ecosystem of policy, financing and community engagement [3].

Despite these barriers, several success stories illustrate how low-cost biomedical devices can be scaled effectively with the right mix of design strategy, partnership and perseverance. One prominent example is the Aravind Eye Care System in India, which developed an intraocular lens that reduced cataract surgery costs by more than 90% and enabled high-volume procedures without compromising quality. Another example is the “Embrace” infant warmer, a low-cost, electricity-independent solution for neonatal hypothermia that has reached thousands of babies across South Asia and Sub-Saharan Africa. The widespread adoption of rapid diagnostic tests (RDTs) for malaria and HIV also demonstrates how global procurement agencies, local governments and manufacturers can align to drive scale. These success stories share common elements: user-centered design, rigorous validation, strong public-private partnerships and integration into health system workflows. Notably, these devices were designed not only to be inexpensive but also durable, intuitive and context-appropriate—meeting users where they are. Localization played a key role, both in manufacturing and in building trust with healthcare workers and patients. Moreover, long-term engagement with local stakeholders ensured that devices were adapted based on feedback and changing needs. In this sense, the design process was ongoing, iterative and deeply collaborative. These examples show that cost-effectiveness is necessary, but not sufficient what truly scales is the combination of technical excellence, contextual relevance and sustained stakeholder investment [4].

Moving forward, scaling low-cost biomedical devices will require systemic interventions that go beyond individual innovations. First, the creation of regulatory fast tracks for essential, low-risk devices can accelerate time to market without compromising safety. Harmonizing standards across regions would further reduce the burden on small developers seeking multi-country approval. Second, investment in local manufacturing and supply chains is vital not only to reduce costs and ensure device availability but also to build national capacity and resilience. Governments and donor organizations should fund procurement mechanisms that prioritize impact and affordability over brand recognition or legacy relationships. Third, innovation hubs and incubators in LMICs should be supported to help local entrepreneurs bring their ideas to scale with business development training, access to capital and mentorship networks. Education and capacity building must also extend to healthcare workers, whose feedback is essential for ensuring usability and adoption. Finally, all stakeholders must recognize that successful scaling is not a linear process but a cyclical one requiring ongoing iteration, adaptation and co-creation. Real-world conditions evolve and technologies must evolve with them. The global health community must adopt a longer view of innovation success one that includes not just invention, but sustainable integration. Only then can we bridge the persistent gap between need and access in the world’s most vulnerable health systems [5].

***Address for Correspondence:** Daniel Torres, Department of Biomedical Engineering, University of Tunis El Manar, Tunis, Tunisia, E-mail: torres.daniel@elmanar.ts

Copyright: © 2025 Torres D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received: 02 June, 2025, Manuscript No. jpbs-25-171766; **Editor Assigned:** 04 June, 2025, PreQC No. P-171766; **Reviewed:** 16 June, 2025, QC No. Q-171766; **Revised:** 23 June, 2025, Manuscript No. R-171766; **Published:** 30 June, 2025, DOI: 10.37421/2155-9538.2025.15.480

Conclusion

Scaling low-cost biomedical devices in global health is both a technical and systemic challenge. While innovation continues to flourish, successful deployment depends on overcoming regulatory, infrastructural and social barriers through thoughtful design and inclusive strategies. Lessons from successful models underscore the importance of local engagement, public-private partnerships and adaptive systems thinking. As the demand for equitable healthcare solutions grows, low-cost biomedical technologies must be supported not just at inception, but throughout the arc of their implementation. Closing the deployment gap is a shared responsibility and a moral imperative in the pursuit of global health equity.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Konishi, Akihito, Soichiro Isobe and Daisaku Sato. "New regulatory framework for medical devices in Japan: Current regulatory considerations regarding clinical studies." *J Vasc Interv Radiol* 29 (2018): 657-660.
2. Boutilier, Justin J., Steven C. Brooks, Alyf Janmohamed and Adam Byers, et al. "Optimizing a drone network to deliver automated external defibrillators." *Circulation* 135 (2017): 2454-2465.
3. Gunasekaran, Dinesh Visva, Rachel Marjorie Wei Wen Tseng, Yih-Chung Tham and Tien Yin Wong. "Applications of digital health for public health responses to COVID-19: A systematic scoping review of artificial intelligence, telehealth and related technologies." *NPJ Digit Med* 4 (2021): 40.
4. Pillai, Sangeeth, Akshaya Upadhyay, Darren Sayson and Bich Hong Nguyen, et al. "Advances in medical wearable biosensors: Design, fabrication and materials strategies in healthcare monitoring." *Molecules* 27 (2021): 165.
5. Fung, Esther Y., Belling Leung, Don Hamilton and John Hope. "Do automated dispensing machines improve patient safety?." *Can J Hosp Pharm* 62 (2009).

How to cite this article: Torres, Daniel. "Scaling Low-cost Biomedical Devices: Challenges and Successes in Global Health Deployment." *J Bioengineer & Biomedical Sci* 15 (2025): 480.